Actualités

Global pharmaceutical company Merck (NYSE:MRK) will be announcing earnings results this Tuesday before market hours. Here’s what investors should know.

The monthly jobs report comes out Friday. Before that, Elon Musk’s SpaceX will post its first earnings report as a listed company. Also reporting: Walt Disney; tech companies Palantir and Advanced Micro Devices; ride-sharing firms Uber and Lyft; private-equity firms Apollo, Carlyle and TPG; and fast-food chains McDonald's and Wendy’s.

In another heavy earnings week, we’ll also see reports from McDonald’s, Disney, Uber, Devon Energy, and more.

Markets enter an earnings-dominated week with a huge concentration of corporate results spanning technology, industrials, healthcare, consumer discretionary, and entertainment sectors. This will provide a critical assessment of economic health and corporate fundamentals amid persistent uncertainty about technology sector valuations and AI infrastructure spending.

Merck (NYSE:MRK) has outlined a global access plan for its investigational once-monthly oral HIV prevention pill, alimatravir. The company is pursuing early voluntary licensing and regional manufacturing across 129 low and middle income countries ahead of Phase 3 completion. New public private partnerships and regulatory engagement aim to prepare health systems for a rapid rollout if the drug is approved. Merck enters this news cycle with its stock at $130.2 and a return of 22.3% year to...

Moderna's Q2 revenue tops estimates, but shares fall after its phase III norovirus vaccine study misses early success criteria.

Eli Lilly stock ran on a story that was public and dated long before the price moved, and reading it right still would not have put you ahead of every peer.

Here is a way to get paid a meaningful income now on your Eli Lilly shares, income you keep no matter what the stock does, in exchange for agreeing to sell at a price above today's if it climbs there.

The ETF industry keeps piling on the covered calls and derivative overlays, but three plain-vanilla dividend funds quietly pay over 4 percent by doing something almost radical: just owning stocks and collecting the cash.

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

Moderna posted a narrower per-share loss and higher revenue in its latest quarter, but shares were tumbling anyway. Moderna posted a loss of $1.97 a share, narrower than the loss of $2.01 Wall Street had anticipated, and slimmer than the per-share loss of $2.13 reported last year. The drugmaker reiterated its full-year guidance of 10% revenue growth, evenly split between U.S. and international sales.

This blockbuster class of drugs is shattering all sales records. Which stock will do better—Eli Lilly or Novo Nordisk?

MRK heads into Q2 earnings with acquisition costs, Keytruda strength and Gardasil challenges likely to shape results. Is the stock still worth holding?

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Merck (MRK), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.

Merck stock has more than doubled over the past five years, and the latest Discounted Cash Flow (DCF) intrinsic value estimate now points to a sizeable gap versus the current share price, while the broader valuation checks suggest a more mixed picture. The roughly 102% total return over five years highlights how strongly the market has rewarded Merck over a full cycle and raises the bar for any further upside to be justified by fundamentals. Recent news around the FDA approval of the oral...

In the most recent trading session, Merck (MRK) closed at $130.36, indicating a -1.11% shift from the previous trading day.

The sticker shock on the pharma giant's shares fades once you look at what investors are paying for the earnings expected just two years from now.

MRNA is likely to face a key Q2 test as investors await results, FDA updates on mRNA-1010 and commercialization plans that could shape its post-COVID growth.

GILD heads into Q2 earnings with HIV franchise strength, rising Yeztugo expectations and oncology progress, even as Cell Therapy faces competitive pressure.

Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Johnson & Johnson stock's oncology engine and its steady guidance raises were on the record quarters before the price moved.

One of the market's strongest health care performers barely moves with the index you already own, and that gap is the whole point.

AbbVie's two newest drugs are growing so fast they've rewritten the company's entire story, and Wall Street may not have fully priced in what happens when the July 31 earnings report confirms it.

Eli Lilly's expanding oncology and newer medicine portfolio is set to play a pivotal role in its Q2 earnings alongside its blockbuster GLP-1 franchise.

Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Merck (NYSE:MRK) reported that KEYTRUDA met its primary endpoint of progression free survival in the Phase 3 KEYNOTE C93 trial for advanced or recurrent endometrial cancer. The company highlighted this as the first time a PD 1 inhibitor has shown a statistically significant benefit over platinum chemotherapy in this patient population. The data are described as a high impact development for Merck's oncology portfolio, with potential implications for future regulatory filings. For investors...

In July 2026, Aurobindo Pharma announced a royalty-free, non-exclusive licensing deal with Merck to supply generic alimatravir for HIV prevention across 129 low- and middle-income countries, while Merck also secured U.S. FDA approval for LIPFENDRA, the first oral PCSK9 inhibitor for lowering LDL cholesterol. Together, these moves highlight Merck’s twin push to expand access to an investigational monthly HIV PrEP pill globally and grow its cardiovascular portfolio with a new oral...

Scribe Therapeutics shares are up 30% since it raised $125 million in its initial public offering Friday. The cash will fund three clinical trials testing whether Scribe’s one-time treatments can halve the risk of heart attacks and strokes. Scribe’s therapies turn off the genetic instructions leading to high levels of damaging lipids, without having to cut a gene’s DNA strands like other one-shot genetic treatments in the clinic.

The drugmaker's rapid stock gains have led to a premium valuation, forcing investors to question its capacity for future growth.

BMY heads into Q2 earnings with growth drugs driving momentum as legacy products decline, setting the stage for a closely watched earnings report.